Journal article
Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS
A Svedbom, F Borgström, E Hernlund, O Ström, V Alekna, ML Bianchi, P Clark, MD Curiel, HP Dimai, M Jürisson, A Uusküla, M Lember, R Kallikorm, O Lesnyak, E McCloskey, O Ershova, KM Sanders, S Silverman, M Tamulaitiene, T Thomas Show all
Quality of Life Research | SPRINGER | Published : 2018
Abstract
Introduction: The International Costs and Utilities Related to Osteoporotic fractures Study is a multinational observational study set up to describe the costs and quality of life (QoL) consequences of fragility fracture. This paper aims to estimate and compare QoL after hip, vertebral, and distal forearm fracture using time-trade-off (TTO), the EuroQol (EQ) Visual Analogue Scale (EQ-VAS), and the EQ-5D-3L valued using the hypothetical UK value set. Methods: Data were collected at four time-points for five QoL point estimates: within 2 weeks after fracture (including pre-fracture recall), and at 4, 12, and 18 months after fracture. Health state utility values (HSUVs) were derived for each fr..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
On its international level, the ICUROS is sponsored by Amgen, Eli Lilly, Medtronic, Novartis, Sanofi-Aventis, Servier, and Pfizer. In Australia, the study was supported by project Grant No. 628422 from the National Health and Medical Research Council with supplementary funding from Merck Pty Ltd. In Austria, the study was sponsored by Central Association of Austrian Social Security Institution (Hauptverband der osterreichischen Sozialversicherungstrager), Austrian Society for Bone and Mineral Research (AuSBMR), Merck Sharp & Dohme, Servier GmbH, Medtronic GmbH, Amgen GmbH, Novartis GmbH, Nycomed GmbH, Roche GmbH, Sanofi-Aventis GmbH, and Daiichi-Sankyo GmbH. In Mexico, the study was supported by CONACyT Grant No. El 2008-01-87106. In Lithuania, the work was supported by the National Osteoporosis Center. In the USA, Amgen Inc., Ingenix Pharmaceutical Services, Eli Lilly and Company, Medtronic Spine LLC, and Pfizer (formerly Wyeth) sponsored the study. Hoffmann La Roche and Amgen provided support. In Estonia, the study was supported by the Estonian Science Foundation [Grant # 9368], and the Estonian Ministry of Education and Research [grants # IUT 34-17, IUT 2-8]. In Russia, the study was supported by Hoffmann La Roche, Amgen, and the Russian Osteoporosis Association.